{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:45:13Z","timestamp":1778049913605,"version":"3.51.4"},"reference-count":142,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T00:00:00Z","timestamp":1439251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The carbohydrate antigens Tn and sialyl-Tn (STn) are expressed in most carcinomas and usually absent in healthy tissues. These antigens have been correlated with cancer progression and poor prognosis, and associated with immunosuppressive microenvironment. Presently they are used in clinical trials as therapeutic vaccination, but with limited success due to their low immunogenicity. Alternatively, anti-Tn and\/or STn antibodies may be used to harness the immune system against tumor cells. Whilst the development of antibodies against these antigens had a boost two decades ago for diagnostic use, so far no such antibody entered into clinical trials. Possible limitations are the low specificity and efficiency of existing antibodies and that novel antibodies are still necessary. The vast array of methodologies available today will allow rapid antibody development and novel formats. Following the advent of hybridoma technology, the immortalization of human B cells became a methodology to obtain human monoclonal antibodies with better specificity. Advances in molecular biology including phage display technology for high throughput screening, transgenic mice and more recently molecularly engineered antibodies enhanced the field of antibody production. The development of novel antibodies against Tn and STn taking advantage of innovative technologies and engineering techniques may result in innovative therapeutic antibodies for cancer treatment.<\/jats:p>","DOI":"10.3390\/biom5031783","type":"journal-article","created":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T10:38:57Z","timestamp":1439289537000},"page":"1783-1809","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Challenges in Antibody Development against Tn and Sialyl-Tn Antigens"],"prefix":"10.3390","volume":"5","author":[{"given":"Liliana","family":"Loureiro","sequence":"first","affiliation":[{"name":"CEDOC, Chronic Diseases Research Center, NOVA Medical School\/Faculdade de Ci\u00eancias M\u00e9dicas, Universidade NOVA de Lisboa, Campo dos M\u00e1rtires da P\u00e1tria, 130, Lisboa 1169-056, Portugal"},{"name":"IBET\u2014Instituto de Biologia Experimental e Tecnol\u00f3gica, Apartado 12, Oeiras 2781-901, Portugal"},{"name":"IHMT, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Rua da Junqueira 100, Lisboa 1349-008, Portugal"}]},{"given":"Myl\u00e8ne","family":"Carrascal","sequence":"additional","affiliation":[{"name":"CEDOC, Chronic Diseases Research Center, NOVA Medical School\/Faculdade de Ci\u00eancias M\u00e9dicas, Universidade NOVA de Lisboa, Campo dos M\u00e1rtires da P\u00e1tria, 130, Lisboa 1169-056, Portugal"}]},{"given":"Ana","family":"Barbas","sequence":"additional","affiliation":[{"name":"IBET\u2014Instituto de Biologia Experimental e Tecnol\u00f3gica, Apartado 12, Oeiras 2781-901, Portugal"}]},{"given":"Jos\u00e9","family":"Ramalho","sequence":"additional","affiliation":[{"name":"CEDOC, Chronic Diseases Research Center, NOVA Medical School\/Faculdade de Ci\u00eancias M\u00e9dicas, Universidade NOVA de Lisboa, Campo dos M\u00e1rtires da P\u00e1tria, 130, Lisboa 1169-056, Portugal"}]},{"given":"Carlos","family":"Novo","sequence":"additional","affiliation":[{"name":"CEDOC, Chronic Diseases Research Center, NOVA Medical School\/Faculdade de Ci\u00eancias M\u00e9dicas, Universidade NOVA de Lisboa, Campo dos M\u00e1rtires da P\u00e1tria, 130, Lisboa 1169-056, Portugal"},{"name":"IHMT, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Rua da Junqueira 100, Lisboa 1349-008, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-7553","authenticated-orcid":false,"given":"Philippe","family":"Delannoy","sequence":"additional","affiliation":[{"name":"Structural and Functional Glycobiology Unit, UMR CNRS 8576, University of Lille, Villeneuve d'Ascq 59655, France"}]},{"given":"Paula","family":"Videira","sequence":"additional","affiliation":[{"name":"CEDOC, Chronic Diseases Research Center, NOVA Medical School\/Faculdade de Ci\u00eancias M\u00e9dicas, Universidade NOVA de Lisboa, Campo dos M\u00e1rtires da P\u00e1tria, 130, Lisboa 1169-056, Portugal"},{"name":"Departamento Ci\u00eancias da Vida, Faculdade de Ci\u00eancias e Tecnologia, Universidade NOVA de Lisboa, Caparica 2829-516, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2015,8,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0959-440X(96)80036-4","article-title":"Carbohydrate recognition systems: Functional triads in cell-cell interactions","volume":"6","author":"Crocker","year":"1996","journal-title":"Curr. Opin. Struct. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1034\/j.1600-065X.2000.917310.x","article-title":"Carbohydrate-mediated recognition systems in innate immunity","volume":"173","author":"Feizi","year":"2000","journal-title":"Immunol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1146\/annurev.biochem.72.121801.161809","article-title":"A genetic approach to mammalian glycan function","volume":"72","author":"Lowe","year":"2003","journal-title":"Annu. Rev. Biochem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/bs.acr.2014.11.002","article-title":"Simple sugars to complex disease\u2014Mucin-type O-glycans in cancer","volume":"126","author":"Kudelka","year":"2015","journal-title":"Adv. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Tuccillo, F.M., de Laurentiis, A., Palmieri, C., Fiume, G., Bonelli, P., Borrelli, A., Tassone, P., Scala, I., Buonaguro, F.M., and Quinto, I. (2014). Aberrant glycosylation as biomarker for cancer: Focus on CD43. Biomed. Res. Int.","DOI":"10.1155\/2014\/742831"},{"key":"ref_6","unstructured":"Varki, A., Cummings, R.D., Esko, J.D., Freeze, H.H., Stanley, P., Bertozzi, C.R., Hart, G.W., and Etzler, M.E. (2009). Essentials of Glycobiology, Cold Spring Harbor Laboratory Press. [2nd ed.]."},{"key":"ref_7","unstructured":"Friedenreich, V. (1930). The Thomsen Haemagglutination Phenomenon, Levin and Munksgaard."},{"key":"ref_8","first-page":"569","article-title":"Acquired hemolytic anemia with polyagglutinability of erythrocytes by a new factor present in normal blood","volume":"73","author":"Moreau","year":"1957","journal-title":"Bull. Mem. Soc. Med. Hop. Paris"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.6729450","article-title":"T and Tn, general carcinoma autoantigens","volume":"224","author":"Springer","year":"1984","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ygyno.2005.07.016","article-title":"Altered mRNA expressions of sialyltransferases in ovarian cancers","volume":"99","author":"Wang","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Videira, P.A., Correia, M., Malagolini, N., Crespo, H.J., Ligeiro, D., Calais, F.M., Trindade, H., and Dall\u2019Olio, F. (2009). ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines. BMC Cancer.","DOI":"10.1186\/1471-2407-9-357"},{"key":"ref_12","first-page":"4605","article-title":"Overexpression of sialyltransferase CMP-sialic acid: Galbeta1,3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas","volume":"61","author":"Schneider","year":"2001","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10719-007-9092-6","article-title":"Surface \u03b12-3- and \u03b12-6-sialylation of human monocytes and derived dendritic cells and its influence on endocytosis","volume":"25","author":"Videira","year":"2008","journal-title":"Glycoconjugate. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1074-7613(00)80180-6","article-title":"The ST3Gal-I sialyltransferase controls CD8+ T lymphocyte homeostasis by modulating O-glycan biosynthesis","volume":"12","author":"Priatel","year":"2000","journal-title":"Immunity"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/1097-0142(19930401)71:7<2191::AID-CNCR2820710705>3.0.CO;2-X","article-title":"Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors","volume":"71","author":"Osako","year":"1993","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1002\/1097-0142(19951115)76:10<1700::AID-CNCR2820761005>3.0.CO;2-Z","article-title":"Expression of thomsen-friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation","volume":"76","author":"Cao","year":"1995","journal-title":"Cancer"},{"key":"ref_17","first-page":"162","article-title":"Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn and T) in gastric mucosa, carcinomas and metastases","volume":"27","author":"David","year":"1992","journal-title":"APMIS Suppl."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jnr.1190","article-title":"Developmental expression of a unique carbohydrate antigen, Tn antigen, in mouse central nervous tissues","volume":"65","author":"Akita","year":"2001","journal-title":"J. Neurosci. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/glycob\/5.3.351","article-title":"Synthesis of O-glycan core 3: Characterization of UDP-GlcNAc: GalNAc-R \u03b23-N-acetyl-glucosaminyltransferase activity from colonic mucosal tissues and lack of the activity in human cancer cell lines","volume":"5","author":"Vavasseur","year":"1995","journal-title":"Glycobiology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/glycob\/4.6.873","article-title":"Alterations of O-glycan biosynthesis in human colon cancer tissues","volume":"4","author":"Yang","year":"1994","journal-title":"Glycobiology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1158\/0008-5472.CAN-07-2345","article-title":"Human tumor antigens Tn and sialyl-Tn arise from mutations in Cosmc","volume":"68","author":"Ju","year":"2008","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"41523","DOI":"10.1074\/jbc.M112.371989","article-title":"Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing Tn antigen","volume":"287","author":"Mi","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1073\/pnas.1305269110","article-title":"Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness","volume":"110","author":"Gill","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1136\/gut.33.4.518","article-title":"Mucin associated Tn and sialosyl-Tn antigen expression in colorectal polyps","volume":"33","author":"Itzkowitz","year":"1992","journal-title":"Gut"},{"key":"ref_25","first-page":"197","article-title":"Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer","volume":"49","author":"Itzkowitz","year":"1989","journal-title":"Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1023\/A:1022200525695","article-title":"Expression of Sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc \u03b12,6-sialyltransferase (ST6GalNAc I) cDNA","volume":"18","author":"Julien","year":"2001","journal-title":"Glycoconjugate J."},{"key":"ref_27","first-page":"1443","article-title":"ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues","volume":"3","author":"Marcos","year":"2011","journal-title":"Front. Biosci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000081003","article-title":"Correlation analysis between tumorous associated antigen sialyl-Tn expression and ST6GalNAc I activity in human colon adenocarcinoma","volume":"67","author":"Cuevas","year":"2004","journal-title":"Oncology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.molonc.2013.03.001","article-title":"Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours","volume":"7","author":"Ferreira","year":"2013","journal-title":"Mol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canlet.2006.08.010","article-title":"Biological significance of cancer-associated sialyl-Tn antigen: Modulation of malignant phenotype in gastric carcinoma cells","volume":"249","author":"Pinho","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10549-004-3137-3","article-title":"Stable expression of sialyl-Tn antigen in T47-D cells induces a decrease of cell adhesion and an increase of cell migration","volume":"90","author":"Julien","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/glycob\/cwj033","article-title":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumorigenicity","volume":"16","author":"Julien","year":"2006","journal-title":"Glycobiology"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Tamura, F., Sato, Y., Hirakawa, M., Yoshida, M., Ono, M., Osuga, T., Okagawa, Y., Uemura, N., Arihara, Y., and Murase, K. (2014). RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells. Gastric Cancer.","DOI":"10.1007\/s10120-014-0454-z"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0046-8177(97)90012-5","article-title":"Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinomas: Relationship with histopathology and prognosis","volume":"28","author":"Ghazizadeh","year":"1997","journal-title":"Hum. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s004280000218","article-title":"Simple mucin-type carbohydrate antigens (Tn, sialosyl-Tn, T and sialosyl-T) and gp 230 mucin-like glycoprotein are candidate markers for neoplastic transformation of the human cervix","volume":"437","author":"Carrilho","year":"2000","journal-title":"Virchows Arch."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1440-1827.1999.00867.x","article-title":"Expression of sialyl-Tn, Tn and T antigens in primary liver cancer","volume":"49","author":"Sasaki","year":"1999","journal-title":"Pathol. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/BF02484612","article-title":"Sialyl-Tn antigen as a useful predictor of poor prognosis in patients with advanced stomach cancer","volume":"28","author":"Terashima","year":"1998","journal-title":"Surg. Today"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0344-0338(96)80148-8","article-title":"Expression of sialyl-Tn in breast cancer. Correlation with prognostic parameters","volume":"192","author":"Soares","year":"1996","journal-title":"Pathol. Res. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/bjc.1994.486","article-title":"Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer","volume":"70","author":"Miles","year":"1994","journal-title":"Br. J. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2004.10.041","article-title":"Tolerance and cancer: Mechanisms of tumor evasion and strategies for breaking tolerance","volume":"22","author":"Mapara","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_41","first-page":"3214","article-title":"T-cell recognition of tumor-associated carbohydrates: The nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity","volume":"57","author":"Meinjohanns","year":"1997","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1074-7613(00)80007-2","article-title":"Crystal structures of two H-2Db\/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity","volume":"10","author":"Glithero","year":"1999","journal-title":"Immunity"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1084\/jem.180.2.739","article-title":"Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes","volume":"180","author":"Haurum","year":"1994","journal-title":"J. Exp. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1002\/eji.1830251211","article-title":"Peptide anchor residue glycosylation: Effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition","volume":"25","author":"Haurum","year":"1995","journal-title":"Eur. J. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/eji.1830260625","article-title":"T cell recognition of Tn-glycosylated peptide antigens","volume":"26","author":"Jensen","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/biom2040435","article-title":"Sialyl-Tn in cancer: (How) did we miss the target?","volume":"2","author":"Julien","year":"2012","journal-title":"Biomolecules"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s281-001-8166-x","article-title":"Antibody repertoires in infants and adults: Effects of T-independent and T-dependent immunizations","volume":"23","author":"Adderson","year":"2001","journal-title":"Springer Semin. Immun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.carres.2014.02.004","article-title":"Glycans in immune recognition and response","volume":"389","author":"Amon","year":"2014","journal-title":"Carbohyd. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1073\/pnas.1115166109","article-title":"Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine","volume":"109","author":"Lakshminarayanan","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1002\/cbic.201402077","article-title":"Immune and anticancer responses elicited by fully synthetic aberrantly glycosylated MUC1 tripartite vaccines modified by a TLR2 or TLR9 agonist","volume":"15","author":"Lakshminarayanan","year":"2014","journal-title":"Chembiochem"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1002\/anie.201104529","article-title":"Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues","volume":"50","author":"Gaidzik","year":"2011","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1039\/c3cs35470a","article-title":"The development of synthetic antitumour vaccines from mucin glycopeptide antigens","volume":"42","author":"Gaidzik","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/ijch.201400131","article-title":"Mucin glycopeptide-protein conjugates\u2014Promising antitumor vaccine candidates","volume":"55","author":"Palitzsch","year":"2015","journal-title":"Isr. J. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Blixt, O., Bueti, D., Burford, B., Allen, D., Julien, S., Hollingsworth, M., Gammerman, A., Fentiman, I., Taylor-Papadimitriou, J., and Burchell, J.M. (2011). Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis. Breast Cancer Res.","DOI":"10.1186\/bcr2841"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/ijc.25778","article-title":"Seromic profiling of colorectal cancer patients with novel glycopeptide microarray","volume":"128","author":"Pedersen","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1038\/bjc.2013.214","article-title":"Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer","volume":"108","author":"Burford","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7150\/jca.7028","article-title":"Survival advantage in patients with metastatic breast cancer receiving endocrine therapy plus sialyl Tn-KHL vaccine: Post hoc analysis of a large randomized trial","volume":"4","author":"Ibrahim","year":"2013","journal-title":"J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1634\/theoncologist.2010-0307","article-title":"Phase III multicenter clinical trial of the sialyl-Tn (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer","volume":"16","author":"Miles","year":"2011","journal-title":"Oncologist"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/sj.bjc.6605083","article-title":"Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model","volume":"100","author":"Julien","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1586\/14760584.3.6.655","article-title":"Vaccination with theratope (STn-KLH) as treatment for breast cancer","volume":"3","author":"Holmberg","year":"2004","journal-title":"Expert Rev. Vaccines"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7797","DOI":"10.1074\/jbc.M110.209742","article-title":"Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses","volume":"286","author":"Freire","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00262-006-0274-z","article-title":"The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma","volume":"56","author":"Saeland","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_63","first-page":"4047","article-title":"Expression of Tn and sialyl-Tn antigens in endometrial cancer: Its relationship with tumor-produced cyclooxygenase-2, tumor- infiltrated lymphocytes and patient prognosis","volume":"26","author":"Ohno","year":"2006","journal-title":"Anticancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bbrc.2008.04.175","article-title":"Down-modulation of B cell signal transduction by ligation of mucins to CD22","volume":"372","author":"Toda","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/glycob\/cws139","article-title":"The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-\u03b2 secretion from monocytes\/macrophages through the DAP12-Syk pathway","volume":"23","author":"Takamiya","year":"2013","journal-title":"Glycobiology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.molonc.2014.02.008","article-title":"Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells","volume":"8","author":"Carrascal","year":"2014","journal-title":"Mol. Oncol."},{"key":"ref_67","first-page":"14","article-title":"Monoclonal antibodies in cancer therapy","volume":"12","author":"Scott","year":"2012","journal-title":"Cancer Immun. Res."},{"key":"ref_68","first-page":"31","article-title":"Therapeutic monoclonal antibodies: ScFv patents as a marker of a new class of potential biopharmaceuticals","volume":"47","author":"Pucca","year":"2011","journal-title":"Braz. J. Pharm. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1263\/jbb.101.284","article-title":"Generation of monoclonal antibodies using simplified single-cell reverse transcription-polymerase chain reaction and cell-free protein synthesis","volume":"101","author":"Ali","year":"2006","journal-title":"J. Biosci. Bioeng."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1073\/pnas.93.15.7843","article-title":"A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities","volume":"93","author":"Babcook","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nprot.2009.3","article-title":"Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen","volume":"4","author":"Smith","year":"2009","journal-title":"Nat. Protoc."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Milstein","year":"1975","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/19420862.2015.989042","article-title":"The therapeutic monoclonal antibody market","volume":"7","author":"Ecker","year":"2015","journal-title":"MAbs"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amsu.2014.09.001","article-title":"The history of monoclonal antibody development\u2014Progress, remaining challenges and future innovations","volume":"3","author":"Liu","year":"2014","journal-title":"Ann. Med. Surg."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nrd984","article-title":"Therapeutic antibodies for human diseases at the dawn of the twenty-first century","volume":"2","author":"Brekke","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: Versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/j.1349-7006.2009.01222.x","article-title":"Engineered therapeutic antibodies with improved effector functions","volume":"100","author":"Kubota","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/35101072","article-title":"Improving the efficacy of antibody-based cancer therapies","volume":"1","author":"Carter","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9097","DOI":"10.1038\/sj.onc.1207104","article-title":"Monoclonal antibody therapeutics and apoptosis","volume":"22","author":"Ludwig","year":"2003","journal-title":"Oncogene"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: Successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Kohne","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2014Mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","article-title":"Rituximab: Mechanism of action","volume":"47","author":"Weiner","year":"2010","journal-title":"Semin. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1158\/0008-5472.CAN-09-2893","article-title":"Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes","volume":"70","author":"Wandall","year":"2010","journal-title":"Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1073\/pnas.78.5.3199","article-title":"A spectrum of monoclonal antibodies reactive with human mammary tumor cells","volume":"78","author":"Colcher","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_88","first-page":"2214","article-title":"Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6 \u03b1-N-acetylgalactosaminyl (sialosyl-Tn) epitope","volume":"48","author":"Kjeldsen","year":"1988","journal-title":"Cancer Res."},{"key":"ref_89","first-page":"4588","article-title":"Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen","volume":"48","author":"Muraro","year":"1988","journal-title":"Cancer Res."},{"key":"ref_90","first-page":"502","article-title":"Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region","volume":"20","author":"Rogers","year":"2005","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_91","first-page":"3364","article-title":"Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen","volume":"55","author":"Zhang","year":"1995","journal-title":"Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-5793(87)80128-X","article-title":"Mucin-carbohydrate directed monoclonal antibody","volume":"215","author":"Kurosaka","year":"1987","journal-title":"FEBS Lett."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1007\/s10620-007-0137-2","article-title":"Immunohistochemical examination of anti-STn monoclonal antibodies LLU9B4, B72.3 and B35.2 for their potential use as tumor markers","volume":"53","author":"Pant","year":"2008","journal-title":"Dig. Dis. Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/CJI.0b013e31827810d1","article-title":"A novel anti-sTn monoclonal antibody 3P9 inhibits human xenografted colorectal carcinomas","volume":"36","author":"An","year":"2013","journal-title":"J. Immunother."},{"key":"ref_95","first-page":"4361","article-title":"Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated \u03b1-N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen","volume":"48","author":"Takahashi","year":"1988","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/0006-291X(90)90488-9","article-title":"A monoclonal antibody directed to Tn antigen","volume":"170","author":"Numata","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1537-2995.1991.31291142945.x","article-title":"Immunochemical studies on the differential binding properties of two monoclonal antibodies reacting with Tn red cells","volume":"31","author":"King","year":"1991","journal-title":"Transfusion"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1006939432665","article-title":"Development and characterization of an antibody directed to an \u03b1-N-acetyl-d-galactosamine glycosylated MUC2 peptide","volume":"15","author":"Reis","year":"1998","journal-title":"Glycoconjugate J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1248\/bpb.31.1739","article-title":"Mouse-human chimeric anti-Tn IgG1 induced anti-tumor activity against Jurkat cells in vitro and in vivo","volume":"31","author":"Ando","year":"2008","journal-title":"Biol. Pharm. Bull."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/glycob\/cwp085","article-title":"A newly generated functional antibody identifies Tn antigen as a novel determinant in the cancer cell-lymphatic endothelium interaction","volume":"19","author":"Danussi","year":"2009","journal-title":"Glycobiology"},{"key":"ref_101","first-page":"303","article-title":"Effects of two monoclonal antibodies MLS128 against Tn-antigen and 1H7 against insulin-like growth factor-I receptor on the growth of colon cancer cells","volume":"6","author":"Zamri","year":"2012","journal-title":"Biosci. Trends"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/glycob\/cwr048","article-title":"A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti-tumor activity","volume":"21","author":"Welinder","year":"2011","journal-title":"Glycobiology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-373-8_1","article-title":"Recent advances and future challenges in glycan microarray technology","volume":"808","author":"Seeberger","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/glycob\/cwl061","article-title":"Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat","volume":"17","author":"Tarp","year":"2007","journal-title":"Glycobiology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/269420a0","article-title":"EB virus-induced B lymphocyte cell lines producing specific antibody","volume":"269","author":"Steinitz","year":"1977","journal-title":"Nature"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/321522a0","article-title":"Replacing the complementarity-determining regions in a human antibody with those from a mouse","volume":"321","author":"Jones","year":"1986","journal-title":"Nature"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1126\/science.4001944","article-title":"Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface","volume":"228","author":"Smith","year":"1985","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-1-61779-931-0_7","article-title":"Hybridoma technology for the generation of monoclonal antibodies","volume":"901","author":"Zhang","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/978-1-62703-992-5_13","article-title":"Cloning, reformatting, and small-scale expression of monoclonal antibody isolated from mouse, rat, or hamster hybridoma","volume":"1131","author":"Loyau","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_110","first-page":"1","article-title":"Human hybridoma technology","volume":"2012","author":"Gorny","year":"2012","journal-title":"Antib. Technol. J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1021\/ed200392h","article-title":"Therapeutic recombinant monoclonal antibodies","volume":"89","author":"Bakhtiar","year":"2012","journal-title":"J. Chem. Educ."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-1-62703-992-5_3","article-title":"Immunization, hybridoma generation, and selection for monoclonal antibody production","volume":"1131","author":"Kim","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_113","first-page":"1","article-title":"Production of monoclonal antibodies","volume":"25","author":"Yokoyama","year":"2006","journal-title":"Curr. Protoc. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0167-5699(00)01668-6","article-title":"Of mice and men: Hybridoma and recombinant antibodies","volume":"21","author":"Little","year":"2000","journal-title":"Immunol. Today"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/imt.11.4","article-title":"Hybridoma technologies for antibody production","volume":"3","author":"Tomita","year":"2011","journal-title":"Immunotherapy"},{"key":"ref_116","first-page":"78","article-title":"Muromonab-CD3 (Orthoclone OKT3): The first monoclonal antibody approved for therapeutic use","volume":"77","author":"Emmons","year":"1987","journal-title":"Iowa Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/348552a0","article-title":"Phage antibodies: Filamentous phage displaying antibody variable domains","volume":"348","author":"McCafferty","year":"1990","journal-title":"Nature"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0065-2776(08)60674-4","article-title":"Human antibodies from combinatorial libraries","volume":"57","author":"Burton","year":"1994","journal-title":"Adv. Immunol."},{"key":"ref_119","first-page":"1","article-title":"Advances in the production of human monoclonal antibodies","volume":"1","author":"Wang","year":"2011","journal-title":"Antib. Technol. J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-62703-586-6_6","article-title":"Production of human monoclonal antibodies by the Epstein-Barr virus method","volume":"1060","author":"Steinitz","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/hyb.1.1982.1.323","article-title":"Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma","volume":"1","author":"Kozbor","year":"1982","journal-title":"Hybridoma"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0165-2478(85)90088-4","article-title":"Human monoclonal antibodies produced by Epstein-Barr virus transformed cell lines bind protein A","volume":"9","author":"Steinitz","year":"1985","journal-title":"Immunol. Lett."},{"key":"ref_123","first-page":"41","article-title":"Establishment of a human lymphoblastoid cell line with specific antibody production against group a streptococcal carbohydrate","volume":"156","author":"Steinitz","year":"1979","journal-title":"Immunobiology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jim.2004.04.007","article-title":"Antibodies from phage antibody libraries","volume":"290","author":"Bradbury","year":"2004","journal-title":"J. Immunol. Methods"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-62703-586-6_14","article-title":"Phage display technology for human monoclonal antibodies","volume":"1060","author":"Deantonio","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.biologicals.2013.04.001","article-title":"Phage display antibodies for diagnostic applications","volume":"41","author":"Bahara","year":"2013","journal-title":"Biologicals"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1089\/hyb.2009.0028","article-title":"Construction and selection of human FAb antibody phage display library of liver cancer","volume":"28","author":"Shui","year":"2009","journal-title":"Hybridoma"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s10330-013-1141-y","article-title":"Application of phage display technology in targeted therapy of breast cancer","volume":"12","author":"Kong","year":"2013","journal-title":"Chin. Ger. J. Clin. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1023\/A:1021215516430","article-title":"Phage display: Practicalities and prospects","volume":"50","author":"Willats","year":"2002","journal-title":"Plant Mol. Biol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Pansri, P., Jaruseranee, N., Rangnoi, K., Kristensen, P., and Yamabhai, M. (2009). A compact phage display human SCFV library for selection of antibodies to a wide variety of antigens. BMC Biotechnol.","DOI":"10.1186\/1472-6750-9-6"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrd1182","article-title":"Adalimumab","volume":"2","author":"Bain","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nbt.2076","article-title":"The discovery and development of belimumab: The anti-BLyS-lupus connection","volume":"30","author":"Stohl","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"D\u00fcbel, S., and Reichert, J.M. (2014). Handbook of Therapeutic Antibodies, Wiley-VCH Verlag GmbH & Co. KGaA.","DOI":"10.1002\/9783527682423"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/glycob\/cwr140","article-title":"Peptide-displaying phage technology in glycobiology","volume":"22","author":"Fukuda","year":"2012","journal-title":"Glycobiology"},{"key":"ref_135","first-page":"3397","article-title":"Novel anti-Tn single-chain Fv-Fc fusion proteins derived from immunized phage library and antibody Fc domain","volume":"30","author":"Kubota","year":"2010","journal-title":"Anticancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0958-1669(95)80093-X","article-title":"Production of fully human antibodies by transgenic mice","volume":"6","author":"Jakobovits","year":"1995","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Tabrizi, M.A., Bornstein, G.G., and Klakamp, S.L. (2012). Development of Antibody-Based Therapeutics, Springer.","DOI":"10.1007\/978-1-4419-5955-3"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nri1837","article-title":"Potent antibody therapeutics by design","volume":"6","author":"Carter","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1745-7254.2005.00135.x","article-title":"Antibody engineering: Facing new challenges in cancer therapy","volume":"26","author":"Sanz","year":"2005","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.coi.2008.06.012","article-title":"Molecular engineering and design of therapeutic antibodies","volume":"20","author":"Presta","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/PPO.0b013e318172d704","article-title":"Antibody-drug conjugates for cancer therapy","volume":"14","author":"Carter","year":"2008","journal-title":"Cancer J."},{"key":"ref_142","first-page":"276","article-title":"Bispecific antibodies for cancer therapy","volume":"12","author":"Chames","year":"2009","journal-title":"Curr. Opin. Drug Discov. Dev."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/5\/3\/1783\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:50:31Z","timestamp":1760215831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/5\/3\/1783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,11]]},"references-count":142,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,9]]}},"alternative-id":["biom5031783"],"URL":"https:\/\/doi.org\/10.3390\/biom5031783","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,11]]}}}